Mandate

Vinge advises Biotage in connection with RWK Bidco’s public tender

April 22, 2025 M&A

On 22 April 2025, RWK Bidco AB, a newly formed company indirectly wholly owned by KKR Funds, announced a public tender offer to the shareholders in Biotage AB to tender all ordinary shares in Biotage to RWK Bidco at a price of SEK 145 in cash per ordinary share.

Biotage is a global supplier and solutions partner to a wide range of customers within drug discovery and development and analytical testing. Headquartered in Sweden, Biotage operates globally serving over 80 countries. The company is listed on Nasdaq Stockholm. The offer values Biotage to approximately SEK 11,607 million based on the total number of ordinary shares in Biotage.

Vinge’s team mainly consists of Dain Hård Nevonen, Joel Magnusson, Benjamin Vafaeian, Lovisa Jonassen, Vilma Henricsson, David Olander and Emelie Schoning.

Related

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge has advised Skeptiva AB in connection with its financing round

Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026